ESPOO, Finland, Jan. 8, 2026 /PRNewswire/ — HUS Helsinki University Hospital and VTT are starting a field test of wearable sensors to develop home dialysis. A totalESPOO, Finland, Jan. 8, 2026 /PRNewswire/ — HUS Helsinki University Hospital and VTT are starting a field test of wearable sensors to develop home dialysis. A total

Wearable sensors assist in developing safer and better home dialysis – HUS and VTT start testing with patients

2026/01/08 15:30
3분 읽기
이 콘텐츠에 대한 의견이나 우려 사항이 있으시면 crypto.news@mexc.com으로 연락주시기 바랍니다

ESPOO, Finland, Jan. 8, 2026 /PRNewswire/ — HUS Helsinki University Hospital and VTT are starting a field test of wearable sensors to develop home dialysis. A total of 36 volunteer patients will use the sensors that enable monitoring of treatment effectivity. Making home dialysis safer and better would improve life quality and save society millions of euros annually.

Currently, dialysis treatment of the kidneys typically requires three weekly hospital visits. It is expensive to society and burdensome for patients, lowering the quality of life and treatment outcomes.

Home dialysis is preferable and much cheaper, but its availability is still limited. Also, because patients typically visit the hospital for follow-up every second or third month, there is a lack of information between visits. Therefore, Helsinki University Hospital (HUS), together with VTT as a technology partner, is starting a field test to monitor home dialysis patients.

“If we could increase home treatment and have a better feeling of its safety, we could improve outcomes and raise the life quality of patients. The whole society could save about eleven million euros per year,” says Virpi Rauta, Lead of CleverHealth Network Ecosystem at Helsinki University Hospital.

VTT’s wearable sensors collect real-time data

Testing involves 36 volunteer patients using wearable sensors developed and made by VTT. As only two patients per week will participate, it will take over six months to gather all data. The sensors gather data on cardiac activity and hemodynamic and oxygen levels.

“Patients are wearing two wirelessly synchronised sensors, and VTT’s algorithms are embedded in the devices and software. We collect and calculate multimodal data before and after dialysis to understand what happens. As engineers, we only understand numbers and patterns and consult experts at HUS to analyse clinical aspects, biochemistry and physiology,” tells Mohammad H. Behfar, Senior Scientist at VTT.

He emphasises the importance of the full design and development chain that VTT manages from conception to pilot fabrication. VTT has long-term experience with ECG patches and medical technology development. In 2023, for instance, VTT announced the one of the first biodegradable ECG patches in the world.

“We believe our wearable sensors are mature enough to support the needs to monitor home dialysis. However, whatever we design, we want a proper field assessment of the technology. What keeps me motivated is the hope of really finding patterns in the data that are meaningful for home dialysis,” Behfar continues.

The project is funded by the Research Council of Finland. Coordination and fine-tuning began already in 2022. Now, all medical and ethical research permits are in order, and testing with pre-recruited patients is ready to begin.

“The study is burdensome for patients because the devices are changed on the second day. But dialysis itself is burdensome, and patients understand that the technology needs to improve,” says Virpi Rauta from HUS.

Still, user acceptance is a classic challenge. “For instance, some most sensitive people might find the adhesive tape of the ECG patch too itchy, while most won’t even notice it after a few minutes. However, in this type of volunteer study, patients are committed,” Behfar says.

Further information:

VTT
Mohammad H. Behfar, Senior Scientist
Mohammadhossein.Behfar@vtt.fi, tel. +358 40 124 2956

HUS Helsinki University Hospital
Virpi Rauta, CleverHealth Network Ecosystem Lead, Development Manager and Nephrologist
Virpi.Rauta@hus.fi, tel. +358 40 528 3147

CONTACT: 

Further information on VTT:
Paula Bergqvist, Communications Manager
+358 20 722 5161, paula.bergqvist@vtt.fi
www.vttresearch.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/vtt-info/r/wearable-sensors-assist-in-developing-safer-and-better-home-dialysis—hus-and-vtt-start-testing-wit,c4289467

The following files are available for download:

https://news.cision.com/vtt-info/i/behfar-wearable-sensors-1,c3499153

Behfar wearable sensors-1

https://news.cision.com/vtt-info/i/wearable-sensors,c3499154

Wearable sensors

Cision View original content:https://www.prnewswire.com/news-releases/wearable-sensors-assist-in-developing-safer-and-better-home-dialysis–hus-and-vtt-start-testing-with-patients-302656197.html

SOURCE VTT Info

면책 조항: 본 사이트에 재게시된 글들은 공개 플랫폼에서 가져온 것으로 정보 제공 목적으로만 제공됩니다. 이는 반드시 MEXC의 견해를 반영하는 것은 아닙니다. 모든 권리는 원저자에게 있습니다. 제3자의 권리를 침해하는 콘텐츠가 있다고 판단될 경우, crypto.news@mexc.com으로 연락하여 삭제 요청을 해주시기 바랍니다. MEXC는 콘텐츠의 정확성, 완전성 또는 시의적절성에 대해 어떠한 보증도 하지 않으며, 제공된 정보에 기반하여 취해진 어떠한 조치에 대해서도 책임을 지지 않습니다. 본 콘텐츠는 금융, 법률 또는 기타 전문적인 조언을 구성하지 않으며, MEXC의 추천이나 보증으로 간주되어서는 안 됩니다.

USD1 Genesis: 0 Fees + 12% APR

USD1 Genesis: 0 Fees + 12% APRUSD1 Genesis: 0 Fees + 12% APR

New users: stake for up to 600% APR. Limited time!